Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

ALS Drug Firm Wins Takeda’s Backing

by Michael McCoy
January 4, 2016 | A version of this story appeared in Volume 94, Issue 1

In its first private equity financing, the start-up Aquinnah Pharmaceuticals has received $5 million from Takeda Pharmaceutical to advance therapies for amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases. Aquinnah says it is developing compounds that break down protein complexes found in the brains of the majority of ALS patients. The Cambridge, Mass.-based firm was cofounded by Manfred Weigele, a chemist who earlier cofounded Ariad Pharmaceuticals.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.